Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents - NO

Mult Scler. 2016 Nov;22(13):1651-1653. doi: 10.1177/1352458516655219. Epub 2016 Jul 29.

Authors

Carla Francisco¹, Jennifer Graves², Emmanuelle Waubant²

Affiliations

¹ Department of Neurology, University of California-San Francisco, San Francisco, CA, USA [email protected].
² Department of Neurology, University of California-San Francisco, San Francisco, CA, USA.

PMID: 27473402
DOI: 10.1177/1352458516655219

No abstract available

MeSH terms

Child
Clinical Trials as Topic
Humans
Immunologic Factors / therapeutic use*
Multiple Sclerosis / drug therapy*
Multiple Sclerosis / therapy
Pediatrics

Substances

Immunologic Factors